肺结核的那些事?

2017-12-12 黄国鑫 上海药讯

近期桃江县第四中学的肺结核事件,引起了全国人民的密切关注。下面就让我们来认识一下,肺结核的那些事?


黄国鑫  上海市东方医院药学部

近期桃江县第四中学的肺结核事件,引起了全国人民的密切关注。下面就让我们来认识一下,肺结核的那些事?

(一)分布

全球有约20亿人曾受到结核分枝杆菌的感染,全球80%的结核病例集中在印度、中国、俄罗斯、南非、秘鲁等22个国家。我国分别在1979、1984/85、1990、2000、2010年进行了5次全国结核病流行病学抽样调查。

(二)分类

肺结核由结核分枝杆菌感染所致,结核分枝杆菌分为人型、牛型、非洲型和鼠型4类,人肺结核的致病菌90%以上为人型结核分枝杆菌,少数为牛型和非洲型分枝杆菌。结核分枝杆菌对干燥、冷、酸、碱等抵抗力强,在干燥的环境中可存活数月或数年。

(三)诊断与传播

由于结核分枝杆菌耐酸染色呈红色,一般细菌无抗酸性,所以抗酸染色是鉴别分枝杆菌和其他细菌的方法之一。因肺结核患者的排菌具有间断性和不均匀性,传染性患者查一次痰也许查不出,所以要多次查痰,通常送3份痰标本,包括清晨痰、夜间痰、即时痰。当痰液里查出结核分枝杆菌的患者才有传染性,主要通过咳嗽、喷嚏、大笑、大声说话等方式把结核分枝杆菌微粒排到空气中传播,即飞沫传播。

儿童、青少年的结核病诊断有参考意义的是结核菌素试验。结核菌素试验反应越强,对结核病的诊断特别是对婴幼儿的结核病诊断越重要。

(四)表现

肺结核的临床表现有咳嗽咳痰(最常见)、发热(多为下午或傍晚开始升高,次晨降至正常)、咯血、胸痛、呼吸困难等。如果出现咳嗽持续2周以上、咯血、午后发热、乏力、盗汗、月经不调或闭经,有肺结核接触史等情况,应考虑肺结核病的可能,及早到医院就诊。

(五)治疗

可供选择的常用治疗药物包括异烟肼、利福平、链霉素、利福喷丁、吡嗪酰胺、乙胺丁醇、对氨基水杨酸钠、阿米卡星、卷曲霉素、氧氟沙星、左氧氟沙星。为保证患者联合、足量的化疗,便于督导管理,市场出现了固定复合剂,即各种药物按固定剂量的配比制成的复合制剂,如由异烟肼、利福平、吡嗪酰胺组成的复合制剂名称为卫非特;由异烟肼、利福平组成的复合制剂名称为卫非宁。

(六)管理

一旦确诊肺结核,根据《中华人民共和国传染病防治法》,肺结核属于乙类传染病,各级医疗机构专人负责,做到及时、准确、完整地报告肺结核疫情。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=272013, encodeId=23832e201309, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Dec 24 07:14:59 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271750, encodeId=03f82e175078, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Dec 23 08:40:01 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271073, encodeId=c45c2e1073a2, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Dec 21 06:34:04 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254123, encodeId=046d125412380, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Dec 14 10:03:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268907, encodeId=0f6126890e6a, content=简单明了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Dec 12 19:34:04 CST 2017, time=2017-12-12, status=1, ipAttribution=)]
    2017-12-24 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=272013, encodeId=23832e201309, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Dec 24 07:14:59 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271750, encodeId=03f82e175078, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Dec 23 08:40:01 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271073, encodeId=c45c2e1073a2, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Dec 21 06:34:04 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254123, encodeId=046d125412380, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Dec 14 10:03:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268907, encodeId=0f6126890e6a, content=简单明了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Dec 12 19:34:04 CST 2017, time=2017-12-12, status=1, ipAttribution=)]
    2017-12-23 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=272013, encodeId=23832e201309, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Dec 24 07:14:59 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271750, encodeId=03f82e175078, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Dec 23 08:40:01 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271073, encodeId=c45c2e1073a2, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Dec 21 06:34:04 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254123, encodeId=046d125412380, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Dec 14 10:03:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268907, encodeId=0f6126890e6a, content=简单明了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Dec 12 19:34:04 CST 2017, time=2017-12-12, status=1, ipAttribution=)]
    2017-12-21 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=272013, encodeId=23832e201309, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Dec 24 07:14:59 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271750, encodeId=03f82e175078, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Dec 23 08:40:01 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271073, encodeId=c45c2e1073a2, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Dec 21 06:34:04 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254123, encodeId=046d125412380, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Dec 14 10:03:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268907, encodeId=0f6126890e6a, content=简单明了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Dec 12 19:34:04 CST 2017, time=2017-12-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=272013, encodeId=23832e201309, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Dec 24 07:14:59 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271750, encodeId=03f82e175078, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Dec 23 08:40:01 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271073, encodeId=c45c2e1073a2, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Dec 21 06:34:04 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254123, encodeId=046d125412380, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Dec 14 10:03:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268907, encodeId=0f6126890e6a, content=简单明了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Dec 12 19:34:04 CST 2017, time=2017-12-12, status=1, ipAttribution=)]
    2017-12-12 天地飞扬

    简单明了.谢谢分享!

    0

相关资讯

PNAS:肺结核患者福音——治疗型肺结核疫苗有望问世!

由南安普敦大学领导的科学家小组在研究工作中迈出了重要的一步,这一研究有望会研制带来有效的疫苗,来对付世界上最致命的传染病,肺结核。

湖南桃江通报中学肺结核突发事件:近九成学生已复学或可复学

2017年8月19日,桃江县第四中学发生肺结核病突发公共卫生应急事件。疫情发生后,县委、县政府高度重视,第一时间启动县级突发公共卫生事件应急预案,并报告省、市疾控中心,立即开展治疗防控工作。

快讯!湖南通报桃江县第二起校园肺结核病疫情

湖南省卫计委20日下午通报湖南省桃江县另一起肺结核疫情。

湖南桃江县肺结核疫情:50名学生已达复学标准

桃江县政府还在新闻发布会现场承诺,及时准确发布疫情信息,并严肃查处此次结核病聚集性疫情处置工作中失职渎职行为。

盘点:近期关于肺结核研究进展一览

【1】Chest:What?他汀还能降低肺结核风险他汀被广泛用于降低胆固醇水平和心血管风险。此外,研究显示他汀或可降低感染疾病和感染相关死亡率的风险;然而,他汀与活动性TB之间的相关性仍不清楚。研究使用中国台湾地区健康保险研究数据库,研究者开展了一项全省范围内的基于人群的研究。纳入2000年至2013年使用他汀,无既往TB疾病的患者。分析了102424例他汀使用者和根据年龄、性别和纳入日期匹配的2

马上评|桃江肺结核事件:追责不是终点,反思才刚开始

湖南桃江四中肺结核事件有了最新消息。桃江县委常委会决定:对县卫计局局长、教育局局长、疾控中心主任等人免职,建议县教育工委免去桃江四中党总支部书记、校长职务。县纪委、监察局将进一步依法依规开展调查,对在此次结核病聚集性疫情处置工作中存在的失职渎职行为予以严肃处理。事件真相逐渐揭开之后,追责总算启动了。但追责并不是我们的终极目的。这样一起重大公共卫生事件发生之后,我们更需要追问的是,从一名学生感染肺结